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To the Editor: We read with interest the report by 
Henningsson et al. (1) on a recent human case of tick-borne 
encephalitis (TBE) in Sweden. This case has multiple simi-
larities to a case in the Netherlands. Until recently, TBE 
virus (TBEV) was not thought to be present in the Nether-
lands. However, detection of TBEV in ticks from a forested 
area in the Netherlands (S. Jahfari et al., Centre for Infec-
tious Disease Control (CIb), RIVM, the Netherlands, pers. 
comm., 2016, Jun 30) led to identification of an autochtho-
nous case of TBE (2). Of note, the presumed incubation 
period in both cases was very short, only 2 days. In both 
cases, quantitative reverse transcription PCR of a tick re-
moved from the patient’s leg showed high levels of TBEV 
RNA. Another similarity between the cases was the ab-
sence of intrathecally produced TBEV antibodies (no IgM 
and a negative antibody index for IgG for the case in the 
Netherlands) at hospital admission. Although 16% of TBE 
patients have no intrathecally produced TBEV antibodies 
at hospital admission, these antibodies are usually impor-
tant for diagnosis (3). These cases underscore the point that 
absence of these antibodies does not rule out TBE. 
By the time patients undergo TBE testing, the virus 
is typically no longer detectable in clinical samples (4). 
Therefore, laboratory diagnosis is done on the basis of the 
presence of antibodies in blood. Flavivirus serologic testing 
is, however, challenging due to cross-reactivity between 
the flaviviruses. Thus, confirmation by virus neutralization 
test is typically required. 
These 2 studies (1,2) show that virus detection in ticks 
from TBE patients can be useful for the definitive diagnosis 
of TBE. However, in low-prevalence settings, it would be in-
efficient to test ticks from all patients with tick bites. In these 
cases, ticks should be tested only when TBE is suspected 
on the basis of compatible clinical symptoms and laboratory 
findings, such as positive TBEV serologic test results.
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